Defining the clinical phenotype of COVID-19 in children

Vania Giacomet; Marta Stracuzzi; Laura Paradiso; Maria Elisabetta Di Cosimo; Valeria Rubinacci; GianVincenzo Zuccotti

doi:10.1111/pai.13355

Defining the clinical phenotype of COVID-19 in children

Pediatr Allergy Immunol. 2020 Nov;31 Suppl 26(Suppl 26):82-84. doi: 10.1111/pai.13355.

Authors

Vania Giacomet¹, Marta Stracuzzi¹, Laura Paradiso², Maria Elisabetta Di Cosimo¹, Valeria Rubinacci¹, GianVincenzo Zuccotti^{1

2}

Affiliations

¹ Paediatric Infectious Disease Unit, Department of Pediatrics, Luigi Sacco Hospital, University of Milan, Milan, Italy.
² Department of Pediatrics, V. Buzzi Children's Hospital, University of Milan, Milan, Italy.

Abstract

On January 7, 2020, a novel coronavirus (SARS-CoV-2) was identified as the causative agent of a cluster of pneumonia of unknown origin detected in Wuhan City by Chinese authorities. Since SARS-CoV-2 discovery, the corresponding disease (COVID-19) has rapidly expanded throughout the globe, making as a consequence the World Health Organization (WHO) declaring a pandemic. As of May 19, 2020, over 4.806.299 cases of COVID-19 had been confirmed worldwide, with more than 318.599 deaths.

Keywords: COVID-19; Italy; SARS-CoV-2; children.

MeSH terms

COVID-19 / etiology*
COVID-19 Drug Treatment
Child
Humans
Phenotype
SARS-CoV-2*